News
EQS-News: Gerresheimer in H1 2025: Bormioli Pharma boosts revenues and earnings, continued market influences in operating business
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
ProKidney (NASDAQ: PROK) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.
The chronic kidney disease-focused biotech
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
Why Nektar Therapeutics Stock Dived by 3% Today
Nektar Therapeutics (NASDAQ: NKTR) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling
EQS-News: Sartorius completes acquisition of MatTek
Why Nektar Therapeutics Stock Was Red-Hot Today
The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering
EQS-News: Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury
EQS-Adhoc: Gerresheimer AG reacts to media reports
EQS-News: Gerresheimer AG: Annual General Meeting approves key proposed resolutions by a large majority
HealthEquity Lifts Outlook on Q1 Growth
HealthEquity (NASDAQ:HQY) reported fiscal 2026 first quarter (ended April 30, 2025) earnings on June 3, 2025, delivering 15% year-over-year revenue growth and raising full-year guidance. Key
EQS-News: Evotec SE: Results of the Annual General Meeting 2025
EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025
EQS-Adhoc: Gerresheimer AG: Adjustment of Guidance for 2025
2 Top Stocks to Buy With Less Than $100
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that
Why Exelixis Stock Is Skyrocketing Today
Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.
EQS-News: Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr
EQS-News: RHÖN-KLINIKUM AG holds steady course in first quarter of 2025 – outlook confirmed
EQS-News: Evotec receives $ 2.5 m grant to generate next generation tuberculosis treatments
EQS-News: Evotec SE reports Q1 2025 results: Paving the way for 2025 growth in soft market environment
Why Lockheed Martin Stock Popped, Then Dropped Today
Lockheed Martin (NYSE: LMT) is riding the market roller coaster on Friday.
In early trading, shares of the defense giant jumped nearly 3% on a Wells Fargo report calling the new fiscal year 2026
EQS-News: Sartorius Supervisory Board extends appointment of board member Alexandra Gatzemeyer
EQS-News: Evotec SE to announce results for the first quarter 2025 on 6 May 2025
Why Biohaven Stock Plummeted by More Than 15% Today
On Friday's news that Biohaven (NYSE: BHVN) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage bi
EQS-News: Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
Why Scholar Rock Holding Stock Topped the Market Today
Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3%